Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A Prospective, Randomized, Parallel-Controlled, Open-Label, Blinded Endpoint (PROBE) Clinical Trial

NCT07602205 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.

NCT NCT07602205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07602205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A Prospective, Randomized, Parallel-Controlled, Open-Label, Blinded Endpoint (PROBE) Clinical Trial
Lead sponsor
Xuanwu Hospital, Beijing
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
December 31, 2027
Enrollment
34 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cdkl5 deficiency disorder